Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

[1]  R. Betts,et al.  Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non‐albicans Candida species , 2014, Mycoses.

[2]  R. Wenzel,et al.  Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. , 2014, International journal of antimicrobial agents.

[3]  H. Ostermann,et al.  Posaconazole prophylaxis – impact on incidence of invasive fungal disease and antifungal treatment in haematological patients , 2013, Mycoses.

[4]  Zhi-xiang Shen,et al.  Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. , 2013, International journal of clinical pharmacology and therapeutics.

[5]  John W. Wilson,et al.  The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole , 2013, American journal of hematology.

[6]  He Huang,et al.  Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  I. Raad,et al.  Comparison of Posaconazole Versus Weekly Amphotericin B Lipid Complex for the Prevention of Invasive Fungal Infections in Hematopoietic Stem-Cell Transplantation , 2012, Transplantation.

[8]  J. Vehreschild,et al.  Patients at High Risk of Invasive Fungal Infections , 2012, Drugs.

[9]  Zhi-xiang Shen,et al.  A Multicenter, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Posaconazole Vs Fluconazole in the Prophylaxis of Invasive Fungal Infection in a Chinese Population , 2011 .

[10]  C. Heussel,et al.  Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation , 2011, British journal of haematology.

[11]  A. Levis,et al.  A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). , 2011, The Journal of antimicrobial chemotherapy.

[12]  C. Gudiol,et al.  Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation , 2011, Bone Marrow Transplantation.

[13]  E. Holler,et al.  Prophylactic Application of Nebulized Liposomal Amphotericin B in Hematologic Patients with Neutropenia , 2011, Oncology Research and Treatment.

[14]  M. Territo,et al.  Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  J. Dipersio,et al.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. , 2010, Blood.

[16]  T. Barbui,et al.  Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  H. Einsele,et al.  Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology , 2009, Haematologica.

[18]  H. Kantarjian,et al.  Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome , 2009, Supportive Care in Cancer.

[19]  K. Matsuo,et al.  Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation , 2008, International journal of hematology.

[20]  W. Hop,et al.  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  B. Thiers.  Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .

[22]  L. Pagano,et al.  Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[24]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[25]  G. Maschmeyer,et al.  Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. , 2007, Drugs.

[26]  E. Thiel,et al.  Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  E. Estey,et al.  Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies , 2006, Antimicrobial Agents and Chemotherapy.

[28]  L. Pagano,et al.  Design and Methods , 2022 .

[29]  T. Walsh,et al.  Reply to Cornely et al. , 2005 .

[30]  O. Cornely,et al.  Choosing a study population for the evaluation of antifungal prophylaxis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  G. Byrnes,et al.  Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[33]  O. Faure,et al.  Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[34]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[35]  E. Radwanski,et al.  Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. , 2003, British journal of clinical pharmacology.

[36]  M. Territo,et al.  Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial , 2003, Annals of Internal Medicine.

[37]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[38]  M A Kish,et al.  Guide to development of practice guidelines. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[40]  G. Mufti,et al.  Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. , 1993, The Journal of antimicrobial chemotherapy.

[41]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.